This week's roundup of Houston innovators includes Robert Kester of Honeywell Rebellion, Serafina Lalany of Houston Exponential, and Shaun Noorian of Empower Pharmacy. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from oil and gas tech to pharmaceuticals — recently making headlines in Houston innovation.

Robert Kester, president and general manager at Honeywell Rebellion

Robert Kester, founder of Rebellion Photonics and president and general manager at Honeywell

Robert Kester joins the Houston Innovators Podcast to discuss his entrepreneurial journey. Photo courtesy of Honeywell

Robert Kester co-founded Rebellion Photonics in 2010. After several years of developing the device that could be used to automate the process and improve safety on oil and gas sites, Kester and his team saw a rising need for the tech — which also meant a need for Rebellion to scale quickly. In 2019, Rebellion exited in an acquisition by Honeywell.

"For us it just made sense that we could team up with Honeywell and figure out how we could scale this thing globally and quickly, so that we could help be a solution for climate change," Kester continues.

Now, as president and general manager at Honeywell Rebellion, Kester still works on his technology under the umbrella of the Honeywell brand. He joined the Houston Innovators Podcast last week to discuss the transition and what he's focused on now. Click here to read more and stream the episode.

Serafina Lalany, interim president of Houston Exponential

Serafina Lalany, vice president of operations at Houston Exponential

Last week, Serafina Lalany is acting as interim identifies the organization's new leader. Photo courtesy of Serafina Lalany

Serafina Lalany, vice president of operations at Houston Exponential, will act as interim executive director for the organization after Harvin Moore, who has served as president of HX since June 2019, announced his resignation last week. HX's Chair Barbara Burger, vice president of innovation at Chevron and president of Chevron Technology Ventures, says Moore is resigning to devote more time to working with growth-stage companies as a mentor, adviser, and investor.

"In a rapidly growing and evolving landscape like this one, we must ensure resources are leveraged for greatest impact," Burger says. "The HX executive committee believes now is an appropriate time re-strategize with the HX organization to ensure it is aligned with the current needs of the innovation ecosystem. While changes may be called for to place resources where they can do the most good, there remains a need for a broad ecosystem champion and HX will continue to serve in that role." Click here to read more.

Shaun Noorian, founder and CEO of Empower Pharmacy

Houston founder talks growth and innovation in the pharmaceuticals industryShaun Noorian, founder and CEO of Empower Pharmacy, joined InnovationMap for a Q&A on his rapidly growing compounding pharmacy business. Photo courtesy of Empower Pharmacy

Shaun Noorian founded Empower Pharmacy so he could create a business that was service focused, and now the company has grown and expanded — and is now working on building two new 85,000-square-foot facilities in Houston. Noorian, in a Q&A with InnovationMap, explained that Houston has been integral to his success.

"I think being in Houston is one of the reasons why we've grown to become the largest compounding pharmacy in the nation," Noorian tells InnovationMap. "I'm sure we're all aware that having the largest medical center in the world in your own backyard is a great way to have more prescribers than pretty much any other city in the country. That definitely helped us and continues to help us grow.

"Additionally, being the third largest city by population means we have a large workforce to pull a diverse workforce for whatever this company needs," he continues. "Having a diverse workforce has been integral in our growth." Click here to read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”